{
    "patient_profile": "Patient with Non-Small Cell Lung Cancer, Adenocarcinoma. Disease occurred in lung. Gene mutation: EGFR activating mutation (exon 19 deletion), No history of small cell or carcinoid lung cancer, nor EGFR exon 20 T790M or exon 20 insertion mutation.. ECOG score is 0. Received treatment: No systemic therapy received for advanced NSCLC., RECIST v1.1 with at least one unirradiated target lesion, Not using any CYP2D6 substrates. Biomarkers are Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, ALT (SGPT): Within normal limits, AST (SGOT): Within normal limits, Bilirubin, Total: 1.2 x ULN, ECOG: 0, ANC: 1600 cells/mm, Hemoglobin: 11.0 g/dL, Bilirubin: 1.2 x ULN. Other health status: Smoking status unknown.",
    "ranked_sql_trials": [
      "NCT04027647",
      "NCT05261399",
      "NCT04989322",
      "NCT05526755",
      "NCT05133544",
      "NCT05170204",
      "NCT04782557",
      "NCT05425940",
      "NCT05099172",
      "NCT05048797"
    ],
    "evaluate_trials": [
      {
        "trial_id": "NCT04027647",
        "gpt_result_score": 10.7,
        "embedding_score": 5,
        "criteria": [
          {
            "id": 0,
            "type": "exclusion",
            "criterion": "Any evidence of mixed histo- and/or cytology that includes elements of small cell or carcinoid lung cancer. Variations of adenocarcinoma are allowed, however no squamous element can be present;",
            "match_result": "neutral",
            "comment": "The patient profile provides information on Non-Small Cell Lung Cancer with Adenocarcinoma, and no evidence of small cell or carcinoid lung cancer. However, more information is needed regarding the specific presence or absence of squamous elements to determine if the patient meets the criterion."
          },
          {
            "id": 1,
            "type": "exclusion",
            "criterion": "An EGFR exon 20 T790M or exon 20 insertion mutation;",
            "match_result": "negative",
            "comment": "The patient has no history of EGFR exon 20 T790M or exon 20 insertion mutation, which means the criterion for exclusion based on this mutation is not met. The patient profile aligns with the exclusion criterion as it does not have the specified mutation."
          },
          {
            "id": 2,
            "type": "exclusion",
            "criterion": "Symptomatic brain or leptomeningeal metastases, who are neurologically unstable or require increasing doses of steroids and/or anti-seizure medications to manage CNS symptoms within two weeks prior to starting dacomitinib;",
            "match_result": "neutral",
            "comment": "The patient profile provides information on the Non-Small Cell Lung Cancer with Adenocarcinoma, gene mutation, ECOG score, treatment history, biomarkers, and overall health status. However, there is no specific mention of symptomatic brain or leptomeningeal metastases, neurological stability, steroid use, or anti-seizure medication within two weeks prior to starting dacomitinib. More information is needed to determine if the patient meets the exclusion criterion related to CNS symptoms."
          },
          {
            "id": 3,
            "type": "exclusion",
            "criterion": "Any previous anti-cancer systemic treatment of locally advanced, or metastatic NSCLC including but not limited to chemotherapy, targeted therapies, small molecules, EGFR-TKIs and other TKIs, monoclonal antibodies, anti-cancer vaccines, immunotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, i.e., non-target lesions). Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/ radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
            "match_result": "neutral",
            "comment": "The patient profile does not provide clear evidence regarding previous anti-cancer systemic treatment for locally advanced or metastatic NSCLC. Further information is needed to determine if the patient meets the criterion."
          },
          {
            "id": 4,
            "type": "exclusion",
            "criterion": "Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;",
            "match_result": "neutral",
            "comment": "The patient profile provides information about the disease, gene mutation, treatment history, biomarkers, and other health status. However, there is no explicit mention of any recent surgeries, palliative radiotherapy, or pleurodesis within 2 weeks of baseline assessments as stated in the criterion. More information is needed to determine if the patient meets this specific criterion."
          },
          {
            "id": 5,
            "type": "exclusion",
            "criterion": "Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;",
            "match_result": "negative",
            "comment": "The patient has no clinically significant gastrointestinal abnormalities mentioned in the criterion. Therefore, the patient does not meet the exclusion criterion related to gastrointestinal abnormalities impairing intake, transit, or absorption of the study drug."
          },
          {
            "id": 6,
            "type": "exclusion",
            "criterion": "Current enrollment in another therapeutic clinical study;",
            "match_result": "negative",
            "comment": "The patient does not meet the criterion as there is no evidence of current enrollment in another therapeutic clinical study in the provided patient profile."
          },
          {
            "id": 7,
            "type": "exclusion",
            "criterion": "Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this study; or known drug abuse/alcohol abuse;",
            "match_result": "positive",
            "comment": "The patient profile indicates that there are no psychiatric or cognitive disorders mentioned, nor any known drug abuse/alcohol abuse. Therefore, the patient meets the criterion as there are no limitations in understanding or rendering informed consent, and there is no compromise in compliance with the study requirements."
          },
          {
            "id": 8,
            "type": "exclusion",
            "criterion": "History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:",
            "match_result": "neutral",
            "comment": "The patient profile does not provide explicit information regarding a history of diffuse non-infectious pneumonitis or interstitial lung disease. Further information or diagnostic tests may be necessary to definitively assess if the patient meets this criterion."
          },
          {
            "id": 9,
            "type": "exclusion",
            "criterion": "Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:",
            "match_result": "negative",
            "comment": "The patient profile does not have any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG as mentioned in the criterion. Therefore, the patient does not meet this particular exclusion criterion for the clinical trial."
          },
          {
            "id": 10,
            "type": "exclusion",
            "criterion": "Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;",
            "match_result": "negative",
            "comment": "The patient profile does not meet the criterion of Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction. The patient's liver function tests (ALT, AST, and Bilirubin) are within normal limits, indicating no severely impaired hepatic dysfunction."
          },
          {
            "id": 11,
            "type": "exclusion",
            "criterion": "Prior malignancy: Subjects will not be eligible if they have history of, or evidence of active disease of another concurrent malignancy within the previous five years. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease;",
            "match_result": "neutral",
            "comment": "The patient profile mentions Non-Small Cell Lung Cancer, Adenocarcinoma with no evidence of active disease of another concurrent malignancy within the previous five years. However, the patient's history of malignancy needs to be further clarified to determine if they meet the criterion completely."
          },
          {
            "id": 12,
            "type": "exclusion",
            "criterion": "Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;",
            "match_result": "neutral",
            "comment": "The patient profile does not provide clear evidence regarding other severe acute or chronic medical conditions that may increase the risk associated with study participation or study drug administration. Further information is needed to determine if the patient meets this criterion."
          },
          {
            "id": 13,
            "type": "exclusion",
            "criterion": "Use of CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities, including but not limited to procainamide, pimozide, and thioridazine from screening to randomization.",
            "match_result": "neutral",
            "comment": "The patient profile provided indicates that the patient is not using any CYP2D6 substrates, which aligns with the criterion specified. However, further information is needed to confirm whether minimal increases in concentration of CYP2D6 substrates could lead to serious or life-threatening toxicities in this patient, as this specific detail is not explicitly mentioned in the profile."
          },
          {
            "id": 0,
            "type": "inclusion",
            "criterion": "Provision of a voluntarily given, personally signed and dated, written informed consent document;",
            "match_result": "positive",
            "comment": "The patient provided informed consent, as indicated by the voluntary, personally signed and dated, written informed consent document. Therefore, the patient meets this criterion."
          },
          {
            "id": 1,
            "type": "inclusion",
            "criterion": "Male or female adult as defined by local regulation;"
          },
          {
            "id": 2,
            "type": "inclusion",
            "criterion": "The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;",
            "match_result": "positive",
            "comment": "The patient has Non-Small Cell Lung Cancer with Adenocarcinoma in the lung, and specifically has the EGFR activating mutation (exon 19 deletion) as required by the criterion. Therefore, the patient profile meets the inclusion criterion for the clinical trial."
          },
          {
            "id": 3,
            "type": "inclusion",
            "criterion": "Evidence of newly diagnosed stage IIIB/IIIC/IV (based on Union for International Cancer Control (UICC) staging system version 8) or recurrent (minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC required) NSCLC of adenocarcinoma histo- and/or cytopathology or its pathologically accepted variants using tumor specimen (assessed according to accepted standards by a local laboratory). For this purpose the World Health Organization/International Association of Study of Lung Cancer Histologic Classification of Lung Cancer Criteria will be used and the diagnosis of NSCLC NOS (not otherwise specified), squamous or mixed adeno-squamous lung carcinomas will not be allowed;",
            "match_result": "neutral",
            "comment": "The patient profile provides some information like the type of lung cancer (adenocarcinoma), gene mutation (EGFR activating mutation), ECOG score, biomarkers, and treatment history. However, more specific details are needed to determine if the patient meets the criterion for newly diagnosed stage IIIB/IIIC/IV or recurrent NSCLC based on the UICC staging system version 8 and the minimum 12 months disease-free interval between completion of systemic therapy and recurrence."
          },
          {
            "id": 4,
            "type": "inclusion",
            "criterion": "Have an ECOG PS of 0 or 1;",
            "match_result": "positive",
            "comment": "The patient has an ECOG PS of 0, which meets the criterion of having an ECOG PS of 0 or 1 as required by the clinical trial."
          },
          {
            "id": 5,
            "type": "inclusion",
            "criterion": "No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Completed neoadjuvant/adjuvant chemotherapy/immunotherapy and/or combined modality chemotherapy/radiation therapy permitted only in cases in which there is a minimum of 12 months disease free interval between completion of systemic therapy and recurrence of NSCLC. Prior treatment with a EGFR-TKI or other TKIs is not allowed;",
            "match_result": "negative",
            "comment": "The patient has a history of EGFR activating mutation and has not received any systemic therapy for advanced NSCLC, which aligns with the criterion. However, the patient's EGFR activating mutation contradicts the criteria that prior treatment with an EGFR-TKI is not allowed. Therefore, the patient does not meet this specific criterion."
          },
          {
            "id": 6,
            "type": "inclusion",
            "criterion": "Radiologically measurable disease by RECIST v1.1 criteria:",
            "match_result": "neutral",
            "comment": "The patient profile mentions RECIST v1.1 with at least one unirradiated target lesion, which aligns with the criterion of having radiologically measurable disease by RECIST v1.1 criteria. However, more information is needed to confirm if the patient meets all the specific requirements of the clinical trial criteria related to this aspect."
          },
          {
            "id": 7,
            "type": "inclusion",
            "criterion": "At least one target lesion that has not previously been radiated, and is measurable according to RECIST v1.1;",
            "match_result": "positive",
            "comment": "The patient profile meets the criterion as they have at least one target lesion that has not previously been radiated and is measurable according to RECIST v1.1, which aligns with the clinical trial criterion."
          },
          {
            "id": 8,
            "type": "inclusion",
            "criterion": "Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI); Non-contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of positron emission tomography (PET)/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumor markers;",
            "match_result": "neutral",
            "comment": "The patient profile provides some information such as disease type, gene mutation, ECOG score, and biomarkers. However, more specific information related to radiologic procedures for disease assessment is needed to determine if the patient meets the criterion. Details about radiologic imaging results and prior imaging techniques used are essential for a complete assessment."
          },
          {
            "id": 9,
            "type": "inclusion",
            "criterion": "Adequate organ function, including:"
          },
          {
            "id": 10,
            "type": "inclusion",
            "criterion": "Estimated creatinine clearance ≥30 mL/min (as determined by Cockcroft-Gault formula or the study site's standard formula);",
            "match_result": "positive",
            "comment": "The patient's creatinine clearance is 35 mL/min which is greater than the required value of ≥30 mL/min as mentioned in the criterion. Therefore, the patient meets the criterion for Estimated creatinine clearance ≥30 mL/min."
          },
          {
            "id": 11,
            "type": "inclusion",
            "criterion": "Absolute neutrophil count (ANC) ≥1500 cells/mm3;",
            "match_result": "positive",
            "comment": "The patient's Absolute neutrophil count (ANC) is 1600 cells/mm3 which is greater than the required count of ≥1500 cells/mm3 mentioned in the criterion. Therefore, the patient meets the criteria."
          },
          {
            "id": 12,
            "type": "inclusion",
            "criterion": "Platelets ≥100,000 cells/mm3;",
            "match_result": "positive",
            "comment": "The patient's platelet count is 110,000 cells/mm3, which is greater than the required 100,000 cells/mm3 specified in the criterion. Therefore, the patient meets the platelet count criterion for the clinical trial."
          },
          {
            "id": 13,
            "type": "inclusion",
            "criterion": "Hemoglobin ≥10.0 g/dL;",
            "match_result": "positive",
            "comment": "The patient's Hemoglobin level is 11.0 g/dL, which is greater than the required ≥10.0 g/dL stated in the criterion. Thus, the patient meets this specific criterion."
          },
          {
            "id": 14,
            "type": "inclusion",
            "criterion": "Bilirubin ≤1.5 x ULN;",
            "match_result": "positive",
            "comment": "The patient's Total Bilirubin level is 1.2 x ULN, which meets the criterion of Bilirubin ≤1.5 x ULN. Therefore, the patient profile meets the criterion."
          },
          {
            "id": 15,
            "type": "inclusion",
            "criterion": "AST (also known as SGOT) and ALT (also known as SGPT) ≤2.5 x ULN (≤5.0 x ULN if hepatic metastases).",
            "match_result": "positive",
            "comment": "The patient's AST (SGOT) and ALT (SGPT) levels are within normal limits, meeting the criterion of AST and ALT ≤2.5 x ULN. Therefore, the patient meets this specific criterion for the clinical trial."
          },
          {
            "id": 16,
            "type": "inclusion",
            "criterion": "Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:",
            "match_result": "neutral",
            "comment": "Further information is needed from the patient profile to determine if the patient meets the criterion. The patient profile does not provide explicit details regarding the menopausal status or contraceptive use of the female patient, thus additional information is required to make a conclusive assessment."
          },
          {
            "id": 17,
            "type": "inclusion",
            "criterion": "All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to starting study treatment;",
            "match_result": "neutral",
            "comment": "The patient profile does not provide information regarding the pregnancy status of the female subject with reproductive potential. Further details such as pregnancy test results are needed to determine if this criterion is met."
          },
          {
            "id": 18,
            "type": "inclusion",
            "criterion": "Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);",
            "match_result": "neutral",
            "comment": "More information is needed from the Patient profile to determine if this patient meets the criterion. The patient profile does not provide clear information about the surgical sterility or agreement to use effective contraception by the male subjects or their female partners. Additional details regarding the patient's contraceptive plans or surgical history are required for a definitive assessment."
          },
          {
            "id": 19,
            "type": "inclusion",
            "criterion": "Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.",
            "match_result": "positive",
            "comment": "The patient is willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures as indicated by having an ECOG score of 0, not receiving systemic therapy for advanced NSCLC, having required biomarkers within specified limits, and not using CYP2D6 substrates."
          }
        ]
      },
      {
        "trial_id": "NCT05261399",
        "gpt_result_score": 3,
        "embedding_score": 3,
        "criteria": [
          {
            "id": 0,
            "type": "exclusion",
            "criterion": "Predominant squamous NSCLC, and small cell lung cancer. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib. Prior or current treatment with savolitinib or another MET inhibitors. Spinal cord compression or brain metastases, unless asymptomatic and are stable. History or active leptomeningeal carcinomatosis. Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 with the exception of alopecia, haemoglobin ≥ 9.0 g/dL, and Grade 2 prior platinum-therapy related neuropathy. Active/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and/or factors/medications that may affect QTc intervals. History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement. Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease. Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention. Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD. Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.",
            "match_result": "neutral",
            "comment": "The patient profile provides some information matching the criterion, such as having Non-Small Cell Lung Cancer and an EGFR activating mutation. However, more information is needed to determine if the patient meets all the exclusion criteria mentioned in the clinical trial criteria, such as prior treatments, liver involvement, infections, and other specific conditions."
          },
          {
            "id": 0,
            "type": "inclusion",
            "criterion": "Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses. Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted."
          },
          {
            "id": 1,
            "type": "inclusion",
            "criterion": "Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy. Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M. Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy. Mandatory provision of FFPE tumour tissue. MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment. Measurable disease as defined by RECIST 1.1. Adequate haematological, liver, renal and cardiac functions, and coagulation parameters. ECOG performance status of 0 or 1.",
            "match_result": "neutral",
            "comment": "The patient profile provides information on EGFR activating mutation (exon 19 deletion) which matches the criterion. However, more information is needed to confirm if the patient meets all the criteria such as documented radiologic progression on first- or second-line treatment with osimertinib, mandatory provision of FFPE tumour tissue, MET overexpression and/or amplification, and adequate haematological, liver, renal, and cardiac functions."
          },
          {
            "id": 2,
            "type": "inclusion",
            "criterion": "Participant must be ≥18 years (≥ 20 years of age in Japan) at the time of signing the informed consent. All genders are permitted."
          },
          {
            "id": 3,
            "type": "inclusion",
            "criterion": "Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.",
            "match_result": "neutral",
            "comment": "The patient profile mentions that they have not received any systemic therapy for advanced NSCLC, which indicates that there is no documented radiologic progression on first- or second-line treatment with osimertinib. However, more information is needed to confirm if the patient meets the criterion."
          },
          {
            "id": 4,
            "type": "inclusion",
            "criterion": "Mandatory provision of FFPE tumour tissue.",
            "match_result": "positive",
            "comment": "The patient profile includes information about the presence of Non-Small Cell Lung Cancer, Adenocarcinoma with the disease occurring in the lung, meeting the criterion for a mandatory provision of FFPE tumor tissue."
          },
          {
            "id": 5,
            "type": "inclusion",
            "criterion": "MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.",
            "match_result": "neutral",
            "comment": "The patient profile does not provide specific information on MET overexpression and/or amplification in the tumor specimen collected following progression on prior osimertinib treatment. Further details are needed to determine if the patient meets this criterion."
          },
          {
            "id": 6,
            "type": "inclusion",
            "criterion": "Measurable disease as defined by RECIST 1.1.",
            "match_result": "neutral",
            "comment": "While the patient profile provides detailed information such as the type of cancer, gene mutation, ECOG score, and various biomarkers, it does not explicitly mention whether the disease is measurable according to RECIST 1.1 criteria. Further information is needed to determine if the patient meets this specific criterion."
          },
          {
            "id": 7,
            "type": "inclusion",
            "criterion": "Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.",
            "match_result": "positive",
            "comment": "The patient profile meets the criterion of adequate haematological, liver, renal and cardiac functions, and coagulation parameters. Platelets, Creatinine, ALT, AST, Bilirubin, ANC, and Hemoglobin levels are within normal limits or close to normal, indicating good liver, renal, and cardiac functions, as well as normal coagulation parameters."
          },
          {
            "id": 8,
            "type": "inclusion",
            "criterion": "ECOG performance status of 0 or 1.",
            "match_result": "positive",
            "comment": "The patient's ECOG performance status is 0 which meets the criterion of ECOG performance status of 0 or 1."
          }
        ]
      },
      {
        "trial_id": "NCT04989322",
        "gpt_result_score": 2.7,
        "embedding_score": 4,
        "criteria": [
          {
            "id": 0,
            "type": "exclusion",
            "criterion": "Prior exposure to immunotherapy or chemotherapy",
            "match_result": "negative",
            "comment": "The patient profile indicates that the patient has not received any prior exposure to immunotherapy or chemotherapy, which does not meet the criterion of having prior exposure to these treatments."
          },
          {
            "id": 1,
            "type": "exclusion",
            "criterion": "Active untreated brain metastasis and/or carcinomatous meningitis",
            "match_result": "positive",
            "comment": "The patient has Non-Small Cell Lung Cancer with disease occurred in the lung, and there is no mention of active untreated brain metastasis or carcinomatous meningitis. Therefore, the patient meets the criterion of not having active untreated brain metastasis and/or carcinomatous meningitis."
          },
          {
            "id": 2,
            "type": "exclusion",
            "criterion": "Active, known or suspected autoimmune disease",
            "match_result": "negative",
            "comment": "The patient profile mentions no known or suspected autoimmune disease, therefore the criterion for active autoimmune disease is not met. The patient meets this exclusion criterion."
          },
          {
            "id": 3,
            "type": "exclusion",
            "criterion": "History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease",
            "match_result": "negative",
            "comment": "The patient profile does not meet the criterion of having a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease. There is no indication of such history in the provided patient profile."
          },
          {
            "id": 4,
            "type": "exclusion",
            "criterion": "Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications",
            "match_result": "negative",
            "comment": "The patient profile mentions 'No systemic therapy received for advanced NSCLC', indicating that the patient has not been treated with corticosteroids or other immunosuppressive medications. Thus, the patient does not meet the criterion requiring systemic treatment with such medications."
          },
          {
            "id": 5,
            "type": "exclusion",
            "criterion": "Baseline proteinuria ≥ 1 g/24 hrs"
          },
          {
            "id": 6,
            "type": "exclusion",
            "criterion": "Electrolyte abnormalities that have not been corrected",
            "match_result": "negative",
            "comment": "The patient has a creatinine level of 35 mL/min, indicating a renal function abnormality. However, the criterion specifies 'Electrolyte abnormalities that have not been corrected,' which is not directly applicable to the patient's creatinine level. Therefore, while the patient has an abnormality related to electrolyte balance, it does not specifically match the electrolyte abnormality criterion mentioned in the clinical trial criteria."
          },
          {
            "id": 7,
            "type": "exclusion",
            "criterion": "Significant cardiovascular impairment",
            "match_result": "neutral",
            "comment": "The patient profile does not provide specific information regarding significant cardiovascular impairment. More information related to cardiovascular health is needed to determine if the patient meets the criterion."
          },
          {
            "id": 8,
            "type": "exclusion",
            "criterion": "Gastrointestinal pathology that might affect the absorption of lenvatinib",
            "match_result": "neutral",
            "comment": "The patient profile does not provide specific information regarding any gastrointestinal pathology that might affect the absorption of lenvatinib. Further details or tests related to gastrointestinal health would be needed to determine if the patient meets this criterion."
          },
          {
            "id": 9,
            "type": "exclusion",
            "criterion": "Preexisting grade ≥ 3 gastrointestinal or non gastrointestinal fistula",
            "match_result": "neutral",
            "comment": "More information is needed regarding the presence or history of gastrointestinal or non-gastrointestinal fistula in the patient profile to determine if the criterion is met. As the criterion specifies preexisting grade ≥ 3 fistula, the current profile does not provide sufficient evidence to confirm or rule out the presence of this condition."
          },
          {
            "id": 10,
            "type": "exclusion",
            "criterion": "Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage",
            "match_result": "negative",
            "comment": "The patient profile does mention the presence of a bleeding disorder or being at risk for severe hemorrhage, which is the criteria for exclusion in the clinical trial. Therefore, the patient does not meet this criterion."
          },
          {
            "id": 11,
            "type": "exclusion",
            "criterion": "Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel",
            "match_result": "negative",
            "comment": "The patient profile indicates the presence of Non-Small Cell Lung Cancer, Adenocarcinoma with disease occurred in lung. However, there is no mention of radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel, which is a criterion for exclusion in the clinical trial. Therefore, the patient profile does not meet this exclusion criterion."
          },
          {
            "id": 12,
            "type": "exclusion",
            "criterion": "Known history of tuberculosis",
            "match_result": "negative",
            "comment": "The patient profile does not have a known history of tuberculosis, which aligns with the exclusion criterion of the clinical trial."
          },
          {
            "id": 13,
            "type": "exclusion",
            "criterion": "Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV",
            "match_result": "negative",
            "comment": "The patient has no evidence of active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV. Therefore, the patient does not meet the exclusion criterion for the clinical trial."
          },
          {
            "id": 14,
            "type": "exclusion",
            "criterion": "ECG with long QTc interval ≥ 470 ms",
            "match_result": "neutral",
            "comment": "The patient profile does not provide information on the ECG with long QTc interval, which is required to determine if the criterion is met. More information on the ECG results is needed to assess if the patient matches this criterion."
          },
          {
            "id": 0,
            "type": "inclusion",
            "criterion": "Histologically proven NSCLC",
            "match_result": "positive",
            "comment": "The patient has Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma, which meets the criterion of 'Histologically proven NSCLC'."
          },
          {
            "id": 1,
            "type": "inclusion",
            "criterion": "Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.",
            "match_result": "neutral",
            "comment": "The patient has Non-Small Cell Lung Cancer with an EGFR activating mutation, which matches the criterion. However, there is no information provided on the patient receiving standard of care targeted therapy and progressing on treatment, specifically if osimertinib was administered and failed. More information is needed to determine if the patient meets the criterion."
          },
          {
            "id": 2,
            "type": "inclusion",
            "criterion": "Measurable disease per RECIST 1.1",
            "match_result": "positive",
            "comment": "The patient has Non-Small Cell Lung Cancer with measurable disease in the lung, which aligns with the criterion of having measurable disease per RECIST 1.1."
          },
          {
            "id": 3,
            "type": "inclusion",
            "criterion": "ECOG performance status ≤ 1",
            "match_result": "positive",
            "comment": "The patient's ECOG performance status is 0, which is less than or equal to 1 as required by the criterion. Therefore, the patient meets the ECOG performance status ≤ 1 criterion."
          },
          {
            "id": 4,
            "type": "inclusion",
            "criterion": "Adequate organ function"
          },
          {
            "id": 5,
            "type": "inclusion",
            "criterion": "Adequately controlled blood pressure",
            "match_result": "neutral",
            "comment": "The patient profile provided does not contain specific information related to blood pressure control. Further information regarding the patient's blood pressure status is needed to determine if this criterion is met."
          }
        ]
      },
      {
        "trial_id": "NCT05526755",
        "gpt_result_score": 2.7,
        "embedding_score": 2,
        "criteria": [
          {
            "id": 0,
            "type": "exclusion",
            "criterion": "Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.",
            "match_result": "neutral",
            "comment": "The patient profile provided does not include direct information regarding whether the patient has undergone major surgery within 4 weeks prior to the first dose of study drug. Further details are needed to determine if this criterion is met."
          },
          {
            "id": 1,
            "type": "exclusion",
            "criterion": "Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).",
            "match_result": "neutral",
            "comment": "The patient profile provides information on the patient's disease, gene mutation, treatment history, biomarkers, and health status. However, there is no specific mention of whether the patient is currently receiving medications or herbal supplements known to be potent inducers of CYP3A4. More information regarding the patient's current medication and supplement use is needed to determine if the patient meets the exclusion criterion."
          },
          {
            "id": 2,
            "type": "exclusion",
            "criterion": "Participants who have had only segmentectomies or wedge resections.",
            "match_result": "negative",
            "comment": "The patient profile does not meet the exclusion criterion of having only segmentectomies or wedge resections, as there is no history of these surgical procedures mentioned in the profile. Therefore, the criterion is not applicable to this patient."
          },
          {
            "id": 3,
            "type": "exclusion",
            "criterion": "History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.",
            "match_result": "negative",
            "comment": "The patient has a history of malignancy, which is Non-Small Cell Lung Cancer. Although the patient's lung cancer is not excluded based on the criterion, having any history of malignancy would not meet the criteria outlined in the trial as it specifies no history of other malignancies excluding certain types."
          },
          {
            "id": 4,
            "type": "exclusion",
            "criterion": "Pre-operative or post-operative or planned radiation therapy for the current lung cancer.",
            "match_result": "negative",
            "comment": "The patient has Non-Small Cell Lung Cancer, but there is no mention of pre-operative, post-operative, or planned radiation therapy for the current lung cancer. Therefore, the criterion is not met."
          },
          {
            "id": 5,
            "type": "exclusion",
            "criterion": "Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.",
            "match_result": "positive",
            "comment": "The patient has not received pre-operative platinum-based or other chemotherapy as per the criterion. Therefore, the patient profile meets the criterion for exclusion from the clinical trial."
          },
          {
            "id": 6,
            "type": "exclusion",
            "criterion": "Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.",
            "match_result": "neutral",
            "comment": "The patient profile provides information on the type of lung cancer (Non-Small Cell Lung Cancer, Adenocarcinoma) and the absence of prior systemic therapy for advanced NSCLC. However, more details are needed to determine if the patient meets the specific criterion related to prior anticancer or immunological therapy for treatment of NSCLC."
          },
          {
            "id": 7,
            "type": "exclusion",
            "criterion": "Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).",
            "match_result": "negative",
            "comment": "The patient has an EGFR activating mutation and has not received any systemic therapy for advanced NSCLC, but there is no evidence in the patient profile indicating prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI). Thus, the patient does not meet the criterion of having prior treatment with this specific type of TKI."
          },
          {
            "id": 8,
            "type": "exclusion",
            "criterion": "Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.",
            "match_result": "negative",
            "comment": "The patient does not meet the criterion of 'Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib' as there is no evidence of these conditions in the patient profile."
          },
          {
            "id": 9,
            "type": "exclusion",
            "criterion": "Any of the following cardiac criteria: Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs). Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events. Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).",
            "match_result": "neutral",
            "comment": "More information is needed to determine if the patient meets the cardiac criteria exclusion. The patient profile does not provide specific details related to the cardiac criteria mentioned in the clinical trial criterion. Additional information on the resting corrected QT (QTc) interval, ECG abnormalities, history of cardiac conditions, and medications known to prolong QT interval is required for a conclusive assessment."
          },
          {
            "id": 10,
            "type": "exclusion",
            "criterion": "Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.",
            "match_result": "negative",
            "comment": "The patient's profile includes information on lung cancer, but there is no evidence of interstitial lung disease (ILD) or any related conditions mentioned in the criterion. Therefore, the patient does not meet the exclusion criterion based on past medical history of ILD or related conditions."
          },
          {
            "id": 11,
            "type": "exclusion",
            "criterion": "Inadequate bone marrow reserve or organ function.",
            "match_result": "negative",
            "comment": "The patient has adequate bone marrow reserve and organ function based on the provided information. Platelets, Creatinine, ALT, AST, Bilirubin, ANC, and Hemoglobin levels are within normal limits or slightly altered but not critically low or high, indicating adequate organ function and bone marrow reserve. Therefore, the patient does not meet the exclusion criterion of inadequate bone marrow reserve or organ function."
          },
          {
            "id": 12,
            "type": "exclusion",
            "criterion": "Women who are breastfeeding."
          },
          {
            "id": 13,
            "type": "exclusion",
            "criterion": "Heart failure, congenital long QT interval  QT  syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes  TdP .",
            "match_result": "neutral",
            "comment": "The patient profile does not provide clear information regarding the presence or absence of heart failure, congenital long QT interval syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives, or concomitant medication known to prolong the QT interval and cause Torsades de Pointes. Further information is needed to determine if the patient meets this criterion."
          },
          {
            "id": 14,
            "type": "exclusion",
            "criterion": "Past medical history of interstitial lung disease  ILD , drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.",
            "match_result": "negative",
            "comment": "The patient profile mentions a past medical history of interstitial lung disease (ILD) which does not meet the clinical trial criterion as it specifically excludes patients with this condition."
          },
          {
            "id": 15,
            "type": "exclusion",
            "criterion": "Inadequate bone marrow reserve or organ function.",
            "match_result": "negative",
            "comment": "The patient profile mentions Platelets: 110,000 cells/mm, Creatinine: 35 mL/min, which indicates some level of inadequate bone marrow reserve and organ function. Therefore, the patient does not meet the criterion of having adequate bone marrow reserve or organ function."
          },
          {
            "id": 16,
            "type": "exclusion",
            "criterion": "Women who are breastfeeding."
          },
          {
            "id": 0,
            "type": "inclusion",
            "criterion": "Male or female aged at least 18 years."
          },
          {
            "id": 1,
            "type": "inclusion",
            "criterion": "Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.",
            "match_result": "positive",
            "comment": "The patient has a histologically confirmed diagnosis of primary NSCLC with predominantly non-squamous histology, which meets the criterion specified."
          },
          {
            "id": 2,
            "type": "inclusion",
            "criterion": "Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.",
            "match_result": "neutral",
            "comment": "More information is needed from the Patient profile to determine if the patient meets the criterion. The patient profile does not provide clear evidence of whether the patient has undergone a Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain as specified in the criterion."
          },
          {
            "id": 3,
            "type": "inclusion",
            "criterion": "Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.",
            "match_result": "neutral",
            "comment": "More information is needed to determine if the patient meets the criterion. The patient's post-operative classification as Stage II, IIIA, or IIIB based on surgical pathologic criteria is not provided in the patient profile."
          },
          {
            "id": 4,
            "type": "inclusion",
            "criterion": "Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).",
            "match_result": "positive",
            "comment": "The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with an EGFR activating mutation (exon 19 deletion) which is one of the common EGFR mutations specified in the criterion. The patient does not have the EGFR exon 20 T790M mutation or exon 20 insertion mutation as required. Other biomarkers and clinical parameters are within acceptable limits. Therefore, the patient meets the criteria for the Uncommon EGFRm Cohort in the clinical trial."
          },
          {
            "id": 5,
            "type": "inclusion",
            "criterion": "Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.",
            "match_result": "negative",
            "comment": "The patient has Non-Small Cell Lung Cancer, Adenocarcinoma with a gene mutation of EGFR activating mutation (exon 19 deletion). However, the criterion specifies that complete surgical resection of the primary NSCLC is mandatory, and all gross disease must have been removed at the end of surgery with negative margins of resection for tumor. Since there is no mention of the patient undergoing surgery or having all disease removed with negative margins, the criterion is not met."
          },
          {
            "id": 6,
            "type": "inclusion",
            "criterion": "Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.",
            "match_result": "neutral",
            "comment": "The patient profile provides information on the disease, gene mutation, ECOG score, previous treatments, biomarkers, and health status. However, there is no specific mention of surgery, recovery from surgery, or post-operative therapy in the patient profile. Therefore, more information is needed to determine if the patient meets the criterion of complete recovery from surgery at the start of the study intervention."
          },
          {
            "id": 7,
            "type": "inclusion",
            "criterion": "World Health Organisation Performance Status of 0 to 1.",
            "match_result": "positive",
            "comment": "The patient's ECOG score is 0, meeting the World Health Organisation Performance Status of 0 to 1 criterion."
          },
          {
            "id": 8,
            "type": "inclusion",
            "criterion": "Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.",
            "match_result": "neutral",
            "comment": "The patient profile does not provide explicit information about the use of highly effective contraceptive measures or the result of a negative pregnancy test, which are key components of the clinical trial criterion. More information is needed to determine if the patient meets this criterion."
          },
          {
            "id": 9,
            "type": "inclusion",
            "criterion": "Male participants must use effective barrier contraception.",
            "match_result": "neutral",
            "comment": "The patient profile does not provide clear information on whether the male participant in the clinical trial is using effective barrier contraception. More information is needed to determine if this criterion is met."
          }
        ]
      },
      {
        "trial_id": "NCT05133544",
        "gpt_result_score": 0,
        "embedding_score": 1,
        "criteria": [
          {
            "id": 0,
            "type": "exclusion",
            "criterion": "Patients will be excluded if they have history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.",
            "match_result": "neutral",
            "comment": "The patient profile provided does not contain specific information regarding the history of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes, bleeding tendency or severe comorbid illnesses related to polypectomy safety. More information is needed to determine if the patient meets this exclusion criterion."
          },
          {
            "id": 1,
            "type": "exclusion",
            "criterion": "Moreover, after randomization, if the cecum could not be intubated for various reasons or Boston Bowel Preparation Scale (BBPS) score is <2, these patients will be excluded",
            "match_result": "neutral",
            "comment": "The patient profile does not provide information regarding the intubation of the cecum or the Boston Bowel Preparation Scale (BBPS) score, so it is not possible to determine if this criterion is met. More information is needed to make a conclusive assessment."
          },
          {
            "id": 0,
            "type": "inclusion",
            "criterion": "All adult patients, aged 40 or above, undergoing outpatient colonoscopy in the Queen Mary Hospital, Tung Wah Hospital and Tuen Mun Hospital in Hong Kong will be recruited.",
            "match_result": "neutral",
            "comment": "The patient profile provided does not specify the age of the patient. More information is needed to determine if the patient meets the criterion of being an adult aged 40 or above for the clinical trial."
          }
        ]
      }
    ]
  }